National Guideline Clearinghouse | Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA 142).

full-text ►

National Guideline Clearinghouse | Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA 142).



National Institute for Health and Care Excellence (NICE)

Guideline Title

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA 142).

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142). London (UK): National Institute for Health and Care Excellence (NICE); 2014 Nov. 47 p. (Technology appraisal guidance; no. 323).

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 May. 36 p. (Technology appraisal guidance; no. 142)

This guideline meets NGC's 2013 (revised) inclusion criteria.